Table of Contents ACTRIMS 2026

Pathogenesis

Is Epstein-Barr virus infection not a prerequisite for MS?

Critical disparities in the diagnostic timeline of MS quantified

 

New therapies and applications

Novel monoclonal antibody obexelimab demonstrates efficacy in phase 2 trial

GLP-1RAs are safe for MS patients but do not alter disease course

 

Remyelination

No remyelinating effects of bazedoxifene in postmenopausal MS patients

 

Follow-up data and subgroup analyses

NEDA sustained for up to 10 years with ocrelizumab in treatment-naïve RMS

New findings support ofatumumab as first-line therapy in early MS

Cladribine is associated with stable or improved cognition over 4 years in RMS

 

Progressive MS

Tolebrutinib is not effective in PPMS in the PERSEUS trial

Fenebrutinib is non-inferior to ocrelizumab in PPMS

 

NMOSD

Daratumumab is a promising novel treatment for NMOSD